Search Results
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Carla Colombo in
Google Scholar
PubMed
Search for other papers by Marina Muzza in
Google Scholar
PubMed
Search for other papers by Gabriele Pogliaghi in
Google Scholar
PubMed
Search for other papers by Sonia Palazzo in
Google Scholar
PubMed
Search for other papers by Guia Vannucchi in
Google Scholar
PubMed
Search for other papers by Leonardo Vicentini in
Google Scholar
PubMed
Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
Search for other papers by Luca Persani in
Google Scholar
PubMed
Search for other papers by Giacomo Gazzano in
Google Scholar
PubMed
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
localization . Molecular and Cellular Endocrinology 399 288 – 295 . ( https://doi.org/10.1016/j.mce.2014.10.019 ) Muzza M Colombo C Pogliaghi G Karapanou O Fugazzola L 2020 Molecular markers for the classification of cytologically indeterminate
Search for other papers by Pei-Pei Xu in
Google Scholar
PubMed
Search for other papers by Su Zeng in
Google Scholar
PubMed
Search for other papers by Xiao-Tian Xia in
Google Scholar
PubMed
Search for other papers by Zi-Heng Ye in
Google Scholar
PubMed
Search for other papers by Mei-Fang Li in
Google Scholar
PubMed
Search for other papers by Ming-Yun Chen in
Google Scholar
PubMed
Search for other papers by Tian Xia in
Google Scholar
PubMed
Search for other papers by Jing-Jing Xu in
Google Scholar
PubMed
Search for other papers by Qiong Jiao in
Google Scholar
PubMed
Search for other papers by Liang Liu in
Google Scholar
PubMed
Search for other papers by Lian-Xi Li in
Google Scholar
PubMed
Search for other papers by Ming-Gao Guo in
Google Scholar
PubMed
highly expressed in FTC tissues, and plays an important role in the carcinogenesis of FTC via Erk1/2 and JNK pathways. Based on FANB and IHC, FAM172A may be a potential molecular marker to differentially diagnose FTC and benign/borderline thyroid
Dipartimento di Biologia e Patologia Cellulare e Molecolare, Istituto di Endocrinologia ed Oncologia Sperimentale ‘G. Salvatore’, Institute of Biology and Molecular Genetics, Department of Surgery, Human Thyroid Cancers Preclinical and Translational Research Program, Department of Pathology, Dipartimento di Studi delle Istituzioni e dei Sistemi Territoriali, ‘L. Califano’, Universita' Federico II, Napoli, Italy
Search for other papers by Roberto Bellelli in
Google Scholar
PubMed
Dipartimento di Biologia e Patologia Cellulare e Molecolare, Istituto di Endocrinologia ed Oncologia Sperimentale ‘G. Salvatore’, Institute of Biology and Molecular Genetics, Department of Surgery, Human Thyroid Cancers Preclinical and Translational Research Program, Department of Pathology, Dipartimento di Studi delle Istituzioni e dei Sistemi Territoriali, ‘L. Califano’, Universita' Federico II, Napoli, Italy
Search for other papers by Maria Domenica Castellone in
Google Scholar
PubMed
Search for other papers by Ginesa Garcia-Rostan in
Google Scholar
PubMed
Search for other papers by Clara Ugolini in
Google Scholar
PubMed
Search for other papers by Carmelo Nucera in
Google Scholar
PubMed
Search for other papers by Peter M Sadow in
Google Scholar
PubMed
Dipartimento di Biologia e Patologia Cellulare e Molecolare, Istituto di Endocrinologia ed Oncologia Sperimentale ‘G. Salvatore’, Institute of Biology and Molecular Genetics, Department of Surgery, Human Thyroid Cancers Preclinical and Translational Research Program, Department of Pathology, Dipartimento di Studi delle Istituzioni e dei Sistemi Territoriali, ‘L. Califano’, Universita' Federico II, Napoli, Italy
Search for other papers by Tito Claudio Nappi in
Google Scholar
PubMed
Dipartimento di Biologia e Patologia Cellulare e Molecolare, Istituto di Endocrinologia ed Oncologia Sperimentale ‘G. Salvatore’, Institute of Biology and Molecular Genetics, Department of Surgery, Human Thyroid Cancers Preclinical and Translational Research Program, Department of Pathology, Dipartimento di Studi delle Istituzioni e dei Sistemi Territoriali, ‘L. Califano’, Universita' Federico II, Napoli, Italy
Search for other papers by Paolo Salerno in
Google Scholar
PubMed
Dipartimento di Biologia e Patologia Cellulare e Molecolare, Istituto di Endocrinologia ed Oncologia Sperimentale ‘G. Salvatore’, Institute of Biology and Molecular Genetics, Department of Surgery, Human Thyroid Cancers Preclinical and Translational Research Program, Department of Pathology, Dipartimento di Studi delle Istituzioni e dei Sistemi Territoriali, ‘L. Califano’, Universita' Federico II, Napoli, Italy
Search for other papers by Maria Carmela Cantisani in
Google Scholar
PubMed
Search for other papers by Fulvio Basolo in
Google Scholar
PubMed
Search for other papers by Tomas Alvarez Gago in
Google Scholar
PubMed
Search for other papers by Giuliana Salvatore in
Google Scholar
PubMed
Dipartimento di Biologia e Patologia Cellulare e Molecolare, Istituto di Endocrinologia ed Oncologia Sperimentale ‘G. Salvatore’, Institute of Biology and Molecular Genetics, Department of Surgery, Human Thyroid Cancers Preclinical and Translational Research Program, Department of Pathology, Dipartimento di Studi delle Istituzioni e dei Sistemi Territoriali, ‘L. Califano’, Universita' Federico II, Napoli, Italy
Search for other papers by Massimo Santoro in
Google Scholar
PubMed
upregulated in a fraction (28.4%) of PTCs and correlated with aggressive PTC variants (tall-cell) and expression of molecular markers of invasiveness, such as metalloproteases. Here, we show that FOXM1 is significantly increased in ATCs compared with WDTCs
Search for other papers by Maria Theresa E Montales in
Google Scholar
PubMed
Arkansas Children’s Hospital Research Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Search for other papers by Stepan B Melnyk in
Google Scholar
PubMed
Search for other papers by Shi J Liu in
Google Scholar
PubMed
The Winthrop P Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Search for other papers by Frank A Simmen in
Google Scholar
PubMed
Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Search for other papers by Y Lucy Liu in
Google Scholar
PubMed
The Winthrop P Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Search for other papers by Rosalia C M Simmen in
Google Scholar
PubMed
expression of CDO and HFDO tumors Tumors from CDO and HFDO were further assessed for molecular markers of early pathologic response to Dox, given the comparable numbers of CDO (5 of 12) and HFDO (6 of 12) whose tumors did not decrease in volume with Dox
Search for other papers by Thais Biude Mendes in
Google Scholar
PubMed
Search for other papers by Bruno Heidi Nozima in
Google Scholar
PubMed
Search for other papers by Alexandre Budu in
Google Scholar
PubMed
Search for other papers by Rodrigo Barbosa de Souza in
Google Scholar
PubMed
Search for other papers by Marcia Helena Braga Catroxo in
Google Scholar
PubMed
Search for other papers by Rosana Delcelo in
Google Scholar
PubMed
Search for other papers by Marcos Leoni Gazarini in
Google Scholar
PubMed
Search for other papers by Janete Maria Cerutti in
Google Scholar
PubMed
). Indeterminate nodules often undergo surgical excision for a definitive diagnosis. For better classification of a disease state and improved clinical decision-making, preoperative molecular markers have been considered. We have previously identified four
Search for other papers by Jens Waldmann in
Google Scholar
PubMed
Search for other papers by Volker Fendrich in
Google Scholar
PubMed
Search for other papers by Julia Holler in
Google Scholar
PubMed
Search for other papers by Malte Buchholz in
Google Scholar
PubMed
Search for other papers by Ernst Heinmöller in
Google Scholar
PubMed
Search for other papers by Peter Langer in
Google Scholar
PubMed
Search for other papers by Annette Ramaswamy in
Google Scholar
PubMed
Search for other papers by Birgit Samans in
Google Scholar
PubMed
Search for other papers by Martin K Walz in
Google Scholar
PubMed
Search for other papers by Matthias Rothmund in
Google Scholar
PubMed
Search for other papers by Detlef K Bartsch in
Google Scholar
PubMed
Search for other papers by Emily P Slater in
Google Scholar
PubMed
benign from malignant PC is not reliable. Malignancy is only proven by the presence of distant or lymph node metastases. Efforts have been made to establish molecular markers for malignancy such as overexpression of HSP90, human telomerase reverse
Search for other papers by Segolene Hescot in
Google Scholar
PubMed
Search for other papers by Abir Al Ghuzlan in
Google Scholar
PubMed
Search for other papers by Theophraste Henry in
Google Scholar
PubMed
Search for other papers by Hala Sheikh-Alard in
Google Scholar
PubMed
Search for other papers by Livia Lamartina in
Google Scholar
PubMed
Search for other papers by Isabelle Borget in
Google Scholar
PubMed
Search for other papers by Julien Hadoux in
Google Scholar
PubMed
Search for other papers by Eric Baudin in
Google Scholar
PubMed
Search for other papers by Corinne Dupuy in
Google Scholar
PubMed
Search for other papers by Alyaksandr V Nikitski in
Google Scholar
PubMed
Search for other papers by Yuri E Nikiforov in
Google Scholar
PubMed
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
Search for other papers by Marina N Nikiforova in
Google Scholar
PubMed
Department of Endocrinology, Hôpitaux Universitaires de Genève, Geneva, Switzerland
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
profiles in this study revealed the presence of molecular markers that can be potentially used for targeted therapies. Among them, two tumors carried NTRK3 fusions, which are targetable by specific and NTRK inhibitors (entrectinib, larotrectinib) with
Search for other papers by Li Cong in
Google Scholar
PubMed
Search for other papers by Jessica Gasser in
Google Scholar
PubMed
Search for other papers by Jessica Zhao in
Google Scholar
PubMed
Search for other papers by Baofeng Yang in
Google Scholar
PubMed
Search for other papers by Fanghong Li in
Google Scholar
PubMed
Search for other papers by Allan Z Zhao in
Google Scholar
PubMed
correlated with its poor prognosis ( Nikaido et al. 1996 ). Similarly, one of the molecular markers of endometrial cancer cells is the elevated level of cyclin E2 ( Oshita et al. 2002 ), which also helps to propel the progression from G 1 - to S
Search for other papers by Stephen Hiscox in
Google Scholar
PubMed
Search for other papers by L Morgan in
Google Scholar
PubMed
Search for other papers by Tim Green in
Google Scholar
PubMed
Search for other papers by Robert I Nicholson in
Google Scholar
PubMed
. Tovey S , Dunne B, Witton CJ, Forsyth A, Cooke TG & Bartlett JM 2005 Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clinical Cancer Research 11 4835 –4842
Search for other papers by Lauren N Pontius in
Google Scholar
PubMed
Search for other papers by Linda M Youngwirth in
Google Scholar
PubMed
Search for other papers by Samantha M Thomas in
Google Scholar
PubMed
Search for other papers by Randall P Scheri in
Google Scholar
PubMed
Search for other papers by Sanziana A Roman in
Google Scholar
PubMed
Search for other papers by Julie A Sosa in
Google Scholar
PubMed
audited. An additional limitation of this study is that NCDB only reports overall survival, without disease-specific survival or recurrence data. Also, the NCDB does not include novel predictors of outcomes, such as molecular markers. As this study is